In a joint risk GlycoGenesys, Inc....
In a joint risk GlycoGenesys, Inc. (Boston, MA) and Elan Corporation (Dublin, Ireland) have treated 20 subdues with GCS-100 for refractory or relapsed pancreatic adenocarcinoma in a Phase 2 clinical trial. The open-label, single-arm program was designed to obtain data regarding the agent's safety and clinical activity at the 20 mg/[msup2] dose flush Using the WHO criteria for
Herbalife Products , Acne Treatment , Breast Hospital Pump , Afslanken |